Merck & Company (MRK) stock prices updated...
 

Merck & Company stock price

Merck & Company latest news:


  • 11/15/2017 14:52:32

    BRIEF-Merck reports 6.5 pct passive stake in Spero Therapeutics as of Nov 6

    * Merck & Co reports 6.5 percent passive stake in Spero Therapeutics Inc as of Nov 6 - SEC Filing​ Source text: [http://bit.ly/2z57b4q] Further company coverage:

  • 11/09/2017 00:18:10

    AstraZeneca Q3 sales weak as it waits for medicine to work

    AstraZeneca's(AZN) drug sales fell 3 percent in the third quarter, hit again by generic competition to former blockbusters like cholesterol pill Crestor, as it looks to new cancer treatments to revive its fortunes. Total revenue, however, rose 9 percent to $6.23 billion, helped by a $997 million payment from Merck & Co (MRK), which struck a cancer drug partnership deal with the British group in July.

  • 10/30/2017 09:16:35

    Cancer-drug setback sends Merck shares down again

    NEW YORK (Reuters) - A setback for Merck & Co's key cancer drug sent the drugmaker's stock swooning on Monday for a second straight session, putting the shares on track for their biggest two-day decline in more than eight years.

  • 10/27/2017 15:58:06

    Merck shares fall deeper into red as European lung-cancer marketing application pulled

    Merck & Co. shares fell in the extended session Friday after the drug maker said it was no longer pursuing market approval for a lung cancer drug in Europe. Merck shares declined 2.3% to $56.91 after hours, adding to a 6.1% drop during Friday's regular session after the company reported a cyberattack in June hurt sales by at least $135 million in the third quarter. Not only did that wipe out earlier gains following an earnings beat, but put Merck shares at a 1.1% loss for the year. Late Friday, Merck said that it had withdrawn its European application for Keytruda to treat metastatic nonsquamous non-small cell lung cancer, but did not list a specific reason for the withdrawal. Earlier in the year, Merck shares slipped 1.7% on July 6 after the company said it was halting three U.S. clinical studies for Keytruda in the treatment of certain blood cancers.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/27/2017 14:33:04

    BRIEF-Merck withdraws European application for Keytruda

    Merck & Co Inc(MRK): * Merck provides update on European application for Keytruda in combination with pemetrexed and carboplatin for first-line treatment of nonsquamous non-small cell lung cancer. * Withdrawn European application for Keytruda in combination with pemetrexed, carboplatin as first-line treatment for metastatic nonsquamous NSCLC.

  • 10/27/2017 13:41:42

    Apple's stock rally stands out for the Dow

    Investors shouldn't give credit to the surging in shares of Intel Corp. and Microsoft Corp. , after both tech-sector heavyweights reported better-than-expected earnings, for the Dow Jones Industrial Average's gain, they should instead thank Apple Inc.'s stock rally. That's because the combined price gain in Intel and Microsoft shares of $9.13, which would about 63 points to the Dow's price, was being cancelled out by the combined price decline in Chevron Corp. and Merck & Co. Inc. shares after the companies' disappointing results of $9.50, which would shave about 65 points off the Dow. So the Dow's 22-point gain can be attributed to the $5.61, or 3.6%, gain in Apple's stock after reports of strong iPhone X demand, which is adding about 39 points to the Dow.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/27/2017 10:23:35

    Nasdaq on track for best daily point rise in more than 2 years as tech sector powers record rally

    The Nasdaq Composite Index was on pace to book its best single-session point gains in more than 2 years on Friday as tech shares soared. The Nasdaq Composite Index was surging 134 points, or 2%, toward a fresh all-time high closing at 6,684, which would mark the best point and percentage gain since a 191.05-point, or 4.2%, climb for the technology-heavy index on Aug. 27, 2015, according to FactSet data. The Nasdaq is marching toward its best gain in 26 months on the back of a series of hotter-than-expected earnings from some of the biggest companies in technology, including Microsoft Corp. and Amazon.com Inc. , which were both trading at record highs after posting quarterly results that surpassed analysts' estimates. Meanwhile, a popular way to invest on the tech sector, the exchange-traded Technology Select Sector SPDR ETF , also was on pace to book its best daily climb since Aug. 26, 2015. Elsewhere, the S&P 500 index was up 0.8% at 2,579.92, while the Dow Jones Industrial Average was trading up 30 points, or 0.1%, at 23,432, as shares of Chevron Corp. and Merck & Co. Inc. capped the blue-chip benchmark's gains. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/27/2017 09:58:45

    Nasdaq on track for best daily point rise in 1 1/2 years as tech sector powers record rally

    The Nasdaq Composite Index was on pace to book its best single-session point gains in 19 months on Friday as tech shares soared. The Nasdaq Composite Index was surging 125 points, or 1.9%, toward a fresh all-time high closing at 6,684, which would mark the best point and percentage gain since a 131.65-point, or 2.9%, climb for the technology-heavy index on March 1, 2016, according to FactSet data. The Nasdaq is marching toward its best gain in more than a year on the back of a series of hotter-than-expected earnings from some of the biggest companies in technology, including Microsoft Corp. and Amazon.com Inc. , which were both trading at record highs after posting quarterly results that surpassed analysts' estimates. Meanwhile, a popular way to invest on the tech sector, the exchange-traded Technology Select Sector SPDR ETF , was on pace to book its best daily climb since Aug. 26, 2015. Elsewhere, the S&P 500 index was up 0.7% at 2,579, while the Dow Jones Industrial Average was trading up 25 points, or 0.1%, at 23,422, as shares of Chevron Corp. and Merck & Co. Inc. capped the blue-chip benchmark's gains. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/27/2017 09:11:35

    Nasdaq on track for best daily rise in nearly a year as technology sector powers record rally

    The Nasdaq Composite Index was on pace to book its best single-session rise since the day before President Donald Trump was elected back in November. The Nasdaq Composite Index was surging 104 points, or 1.6%, toward a fresh all-time high closing at 6,664.04, which would mark the best point and percentage gain since a 119.80-point, or 2.4%, climb for the technology-heavy index on Nov. 7, 2016, according to FactSet data. The Nasdaq is marching toward its best gain in nearly a year on the back of a series of hotter-than-expected earnings from some of the biggest companies in technology, including Microsoft Corp. and Amazon.com Inc. , which were both trading at record highs after posting quarterly results that surpassed analysts' estimates. Meanwhile, a popular way to invest on the tech sector, the exchange-traded Technology Select Sector SPDR ETF , was on pace to book its best daily climb since March 1, 2016. Elsewhere, the S&P 500 index was up 0.7% at 2,576, while the Dow Jones Industrial Average was trading up 25 points, or 0.1%, at 23,422, as shares of Chevron Corp. and Merck & Co. Inc. capped the blue-chip benchmark's gains. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/27/2017 08:47:22

    Nasdaq Composite on track for best daily rise since before Election Day as tech powers record rally

    The Nasdaq Composite Index was on pace to book its best single-session rise since the day before President Donald Trump was elected back in November. The Nasdaq Composite Index was surging 96 points, or 1.5%, toward a fresh all-time high closing at 6,651, which would mark the best point and percentage gain since a 119.80-point, or 2.4%, climb for the technology-heavy index on Nov. 7, 2016, according to FactSet data. The Nasdaq is marching toward its best gain in nearly a year on the back of a series of hotter-than-expected earnings from some of the biggest companies in technology, including Microsoft Corp. and Amazon.com Inc. , which were both trading at record highs after posting quarterly results that surpassed analysts' estimates. Meanwhile, a popular way to invest on the tech sector, the exchange-traded Technology Select Sector SPDR ETF was on pace to book its best daily climb since March 1, 2016. Elsewhere, the S&P 500 index was up 0.5% at 2,572, while the Dow Jones Industrial Average was trading flat at 23,407, as shares of Chevron Corp. and Merck & Co. Inc. weighed on the blue-chip benchmark. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/27/2017 07:38:01

    Dow dragged lower by Chevron, Merck; S&P 500, Nasdaq rally at the open on tech earnings

    U.S. stock benchmarks opened mostly higher on Friday, supported by data showing the U.S. economy expanded at a solid 3% annual pace for a second straight quarter despite damages from two hurricanes. A strong spate of quarterly results from technology giants, Amazon.com Inc. and Microsoft Corp. , also helped lead the way higher. The Dow Jones Industrial Average , however, lagged behind the other equity gauges, down 29 points, or 0.1%, at 23,370, as shares of Chevron Corp. and Merck & Co. Inc. weighed on the price-weighted average. The Nasdaq Composite Index surged 72 points, or 1.1% at 6,632, while the S&P 500 index added 7 points, or 0.3%, at 2,567. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/25/2017 23:16:39

    UK Stocks-Factors to watch on Oct 26

    Oct 26 (Reuters) - Britain's FTSE 100 index is seen opening up 16 points at 7,463.5 on Thursday, according to financial bookmakers. * GLAXOSMITHKLINE: The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax. * GSK/RB: Pfizer to kick off auction process for its consumer healthcare business in November, paving the way for a potentia

  • 10/25/2017 10:02:54

    U.S. committee recommends GSK shingles vaccine over Merck rival

    LONDON, Oct 25 (Reuters) - The committee responsible for U.S. vaccination schedules has given a preferential recommendation to GlaxoSmithKline's newly approved shingles vaccine Shingrix over Merck & Co's established product Zostavax.

  • 10/20/2017 10:45:12

    Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care

    (Reuters) - Drugmaker Merck & Co Inc , moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday.

  • 10/20/2017 10:15:37

    Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care

    (Reuters) - Drugmaker Merck & Co Inc, moving to a new sales team structure in the United States, plans to cut 1,800 sales positions, while adding 960 jobs to a new chronic care sales force, the company said on Friday.

  • 10/19/2017 11:29:46

    Merck cyber attack may cost insurers $275 mln -Verisk's PCS

    NEW YORK, Oct 18 (Reuters) - Insurers could pay $275 million to cover the insured portion of drugmaker Merck & Co's loss from a cyber attack in June, according to a forecast by Verisk Analytics Inc's Property Claim Services (PCS) unit.

  • 09/29/2017 05:09:40

    Merck discontinues development program for a Hep-C treatment

    Merck & Co. said Friday it would discontinue the development of the investigational combination regimens MK-3682B and MK-3682C for the treatment of chronic hepatitis C, after a review of available Phase 2 efficacy data. The drug maker also considered the growing number of treatment options available, including Merck's own Zepatier. "We will continue to study ZEPATIER to understand even more about its role in treating chronic hepatitis C infection and will continue to work with others to help bring Zepatier to appropriate patients with chronic hepatitis C genotype 1 or 4 infection, the genotypes which make up the majority of patients with chronic hepatitis C infection," said Eliav Barr, senior vice president at Merck Research Laboratories. The stock, which was inactive in premarket trade, has slipped 0.1% over the past three months, while the SPDR S&P Pharmaceuticals ETF has shed 2.3% and the Dow Jones Industrial Average has gained 5.1%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/06/2017 10:28:43

    Merck to buy privately-held biotech Rigontec for 115 mln euros upfront

    Merck & Co. said Wednesday that it will acquire privately-held biotech Rigontec for €115 million ($137 million) upfront to Rigontec's shareholders and up to €349 million ($416 million) in additional milestone-contingent payments. Germany-based Rigontec develops RNA-based immunotherapeutics to treat cancer and viral diseases. The company's approach "complements our strategy and our current pipeline," said Merck Research Laboratories' Dr. Eric Rubin. "We think this is an interesting early stage deal that has potential synergy with other [immuno-oncology] agents, although there may be some safety concerns related to immune stimulation in general," said EvercoreISI analyst Umer Raffat. Raffat also noted that it's an early-stage deal: Rigontec's lead product is currently in early-stage trials with an expected readout by the end of 2019. Merck shares rose 0.5% in light trade midday Wednesday. Shares have declined 1.1% over the last three months, compared with a 1.4% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Mercury General CorporationMCY | Meredith CorporationMDP | Meritage CorporationMTH | MeritorMTOR | Merrill Lynch & Co.MER^D | Merrill Lynch & Co.MER^E | Merrill Lynch & Co.MER^F | Merrill Lynch & Co.MER^K | Merrill Lynch & Co.MER^M | Merrill Lynch & Co.MER^P |